In Vivo CRO市場：タイプ別、GLPタイプ別、適応症別-2025～2030年世界予測

In Vivo CRO市場の2023年の市場規模は44億6,000万米ドルで、2024年には48億7,000万米ドルに達すると予測され、CAGR 9.75％で成長し、2030年には85億6,000万米ドルに達すると予測されています。

In Vivo受託研究機関（CRO）は、製薬、バイオテクノロジー、関連産業に、生きた動物モデルを使用する外部委託研究サービスを提供することを専門としています。In Vivo CROの必要性は、前臨床開発における重要な役割に起因しており、毒性学、薬理学、薬剤代謝研究などの包括的なサービスを提供することで、顧客が効率的に第Ⅰ相検査を実施できるようにします。これらのサービスの用途は、創薬、安全性評価、薬事申請サポートに及び、製薬会社、バイオテクノロジー企業、研究機関などを主要なエンドユーザーとしています。市場成長の原動力となっているのは、研究開発費の増加、先進的医療ソリューションに対する需要の高まり、必要な検査から得られるより正確なデータを通じて動物実験を減らすという倫理的な推進力です。主要影響要因としては、トランスレーショナルリサーチにおける技術的進歩、バイオ医薬品パイプラインの拡大、CROと学術機関の連携などが挙げられます。最近の動向では、個別化医療研究、特殊な疾患モデル、新興市場への進出における潜在的なビジネス機会が強調されています。このような機会を捉えるための提言として、CRISPRやAIを活用したデータ分析などの最先端技術に投資し、予測精度と効率を高めることが挙げられます。In Vivo CRO市場は成長の可能性があるにもかかわらず、厳しい規制要求、動物福祉に関する倫理的懸念、高い運営コストなどの課題に直面しています。これらを克服するために、企業は透明性の高い倫理的プラクティスを提唱し、3R（代替、削減、改良）を達成するための代替手法に投資し、プロセスを合理化するための自動化に注力すべきです。革新的なセグメントとしては、臓器オンチップのような、より人間に関連したモデルの開発や、リソースの利用を最小化するための予測分析におけるAIの役割の探求などがあります。市場は急速な技術革新と規制状況を特徴とするダイナミックな性質を示し、利害関係者は事業の成長を維持し競合を維持するために適応力と先見性を維持する必要があります。

市場力学：急速に進化するIn Vivo CRO市場の主要市場洞察を公開

In Vivo CRO市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネス機会の獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 経済的メリットによるアウトソーシングサービスの利用増加
  • 官民による医薬品研究への投資の増加
  • バイオシミラー医薬品や医薬品の開発への注目の高まり
• 市場抑制要因
  • 臨床検査プロセスに関連する高コスト
• 市場機会
  • 臨床検査プロセスのグローバリゼーション
  • 特許申請による医薬品セグメントの競合情勢
• 市場課題
  • In vivo CROの品質管理に関する問題

ポーターのファイブフォース：In Vivo CRO市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：In Vivo CRO市場における外部からの影響の把握

外部マクロ環境要因は、In Vivo CRO市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：In Vivo CRO市場における競合情勢の把握

In Vivo CRO市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：In Vivo CRO市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、In Vivo CRO市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：In Vivo CRO市場における成功への道筋を描く

In Vivo CRO市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 経済的利益によるアウトソーシングサービスの利用増加
    • 官民両部門による医薬品調査への投資増加
    • バイオシミラー医薬品・医薬品の開発への注目が高まる
  • 抑制要因
    • 臨床検査プロセスに関連する高コスト
  • 機会
    • 臨床検査プロセスのグローバリゼーション
    • 特許出願を伴う医薬品セグメントの競合情勢
  • 課題
    • In vivo CROにおける品質管理に関する問題
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 In Vivo CRO市場：タイプ別

• イントロダクション
• 非齧歯類
• 齧歯類
  • マウス
  • ラット

第7章 In Vivo CRO市場：GLPタイプ別

• イントロダクション
• GLP
  • 社内
  • アウトソーシング
• 非GLP
  • 社内
  • アウトソーシング

第8章 In Vivo CRO市場：適応症別

• イントロダクション
• 自己免疫疾患/炎症性疾患
  • 過敏性腸症候群
  • 多発性硬化症
  • 変形性関節症
  • 関節リウマチ
• 血液がん
• 中枢神経系の状態
  • 筋萎縮性側索硬化症
  • てんかん
  • ハンチントン病
  • 筋肉の再生
  • パーキンソン病
  • 脳卒中
  • 外傷性脳損傷
• 糖尿病
• 肥満
• 腫瘍学
• 疼痛管理
  • 急性疼痛
  • 慢性疼痛
• 固形腫瘍
  • 患者由来異種移植
  • 同系モデル
  • 異種移植

第9章 南北アメリカのIn Vivo CRO市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋のIn Vivo CRO市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのIn Vivo CRO市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Charles River Laboratories
• Crown Bioscience, Inc.
• Eurofins Scientific SE
• Evotec SE
• ICON Plc
• Labcorp Drug Development
• Medpace, Inc.
• MI Bioresearch, Inc.
• Parexel International Corporation
• Pharmacology Discovery Services
• PPD Inc.
• Syneos Health
• Syngene International Limited
• Taconic Biosciences, Inc.
• WuXi AppTec, Inc.

LIST OF FIGURES

• FIGURE 1. IN VIVO CRO MARKET RESEARCH PROCESS
• FIGURE 2. IN VIVO CRO MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL IN VIVO CRO MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL IN VIVO CRO MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL IN VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL IN VIVO CRO MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL IN VIVO CRO MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL IN VIVO CRO MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL IN VIVO CRO MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS IN VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS IN VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES IN VIVO CRO MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES IN VIVO CRO MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. IN VIVO CRO MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. IN VIVO CRO MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. IN VIVO CRO MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL IN VIVO CRO MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL IN VIVO CRO MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. IN VIVO CRO MARKET DYNAMICS
• TABLE 7. GLOBAL IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL IN VIVO CRO MARKET SIZE, BY NON-RODENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL IN VIVO CRO MARKET SIZE, BY RODENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL IN VIVO CRO MARKET SIZE, BY MICE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL IN VIVO CRO MARKET SIZE, BY RATS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL IN VIVO CRO MARKET SIZE, BY IN HOUSE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL IN VIVO CRO MARKET SIZE, BY OUTSOURCING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL IN VIVO CRO MARKET SIZE, BY NON-GLP, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL IN VIVO CRO MARKET SIZE, BY IN HOUSE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL IN VIVO CRO MARKET SIZE, BY OUTSOURCING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL IN VIVO CRO MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL IN VIVO CRO MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL IN VIVO CRO MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL IN VIVO CRO MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL IN VIVO CRO MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL IN VIVO CRO MARKET SIZE, BY ALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL IN VIVO CRO MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL IN VIVO CRO MARKET SIZE, BY HUNTINGTON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL IN VIVO CRO MARKET SIZE, BY MUSCLE REGENERATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL IN VIVO CRO MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL IN VIVO CRO MARKET SIZE, BY STROKE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL IN VIVO CRO MARKET SIZE, BY TRAUMATIC BRAIN INJURY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL IN VIVO CRO MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL IN VIVO CRO MARKET SIZE, BY OBESITY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL IN VIVO CRO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL IN VIVO CRO MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL IN VIVO CRO MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 45. GLOBAL IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 46. GLOBAL IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 47. GLOBAL IN VIVO CRO MARKET SIZE, BY PATIENT-DERIVED XENOGRAFT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 48. GLOBAL IN VIVO CRO MARKET SIZE, BY SYNGENEIC MODEL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 49. GLOBAL IN VIVO CRO MARKET SIZE, BY XENOGRAFT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 50. GLOBAL IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
• TABLE 51. AMERICAS IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. AMERICAS IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
• TABLE 53. AMERICAS IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
• TABLE 54. AMERICAS IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 55. AMERICAS IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
• TABLE 56. AMERICAS IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 57. AMERICAS IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 58. AMERICAS IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 59. AMERICAS IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 60. AMERICAS IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
• TABLE 61. AMERICAS IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 62. ARGENTINA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 63. ARGENTINA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
• TABLE 64. ARGENTINA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
• TABLE 65. ARGENTINA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 66. ARGENTINA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
• TABLE 67. ARGENTINA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 68. ARGENTINA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 69. ARGENTINA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 70. ARGENTINA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 71. ARGENTINA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
• TABLE 72. BRAZIL IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. BRAZIL IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
• TABLE 74. BRAZIL IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
• TABLE 75. BRAZIL IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 76. BRAZIL IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
• TABLE 77. BRAZIL IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 78. BRAZIL IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 79. BRAZIL IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 80. BRAZIL IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 81. BRAZIL IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
• TABLE 82. CANADA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. CANADA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
• TABLE 84. CANADA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
• TABLE 85. CANADA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 86. CANADA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
• TABLE 87. CANADA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 88. CANADA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 89. CANADA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 90. CANADA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 91. CANADA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
• TABLE 92. MEXICO IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 93. MEXICO IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
• TABLE 94. MEXICO IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
• TABLE 95. MEXICO IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 96. MEXICO IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
• TABLE 97. MEXICO IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 98. MEXICO IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 99. MEXICO IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 100. MEXICO IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 101. MEXICO IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
• TABLE 102. UNITED STATES IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 103. UNITED STATES IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
• TABLE 104. UNITED STATES IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
• TABLE 105. UNITED STATES IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 106. UNITED STATES IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
• TABLE 107. UNITED STATES IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 108. UNITED STATES IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 109. UNITED STATES IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 110. UNITED STATES IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 111. UNITED STATES IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
• TABLE 112. UNITED STATES IN VIVO CRO MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 113. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 114. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
• TABLE 115. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
• TABLE 116. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 117. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
• TABLE 118. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 119. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 120. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 121. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 122. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
• TABLE 123. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 124. AUSTRALIA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. AUSTRALIA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
• TABLE 126. AUSTRALIA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
• TABLE 127. AUSTRALIA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 128. AUSTRALIA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
• TABLE 129. AUSTRALIA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 130. AUSTRALIA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 131. AUSTRALIA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 132. AUSTRALIA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 133. AUSTRALIA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
• TABLE 134. CHINA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 135. CHINA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
• TABLE 136. CHINA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
• TABLE 137. CHINA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 138. CHINA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
• TABLE 139. CHINA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 140. CHINA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 141. CHINA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 142. CHINA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 143. CHINA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
• TABLE 144. INDIA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 145. INDIA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
• TABLE 146. INDIA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
• TABLE 147. INDIA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 148. INDIA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
• TABLE 149. INDIA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 150. INDIA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 151. INDIA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 152. INDIA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 153. INDIA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
• TABLE 154. INDONESIA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 155. INDONESIA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
• TABLE 156. INDONESIA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
• TABLE 157. INDONESIA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 158. INDONESIA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
• TABLE 159. INDONESIA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 160. INDONESIA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 161. INDONESIA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 162. INDONESIA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 163. INDONESIA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
• TABLE 164. JAPAN IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 165. JAPAN IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
• TABLE 166. JAPAN IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
• TABLE 167. JAPAN IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 168. JAPAN IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
• TABLE 169. JAPAN IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 170. JAPAN IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 171. JAPAN IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 172. JAPAN IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 173. JAPAN IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
• TABLE 174. MALAYSIA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 175. MALAYSIA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
• TABLE 176. MALAYSIA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
• TABLE 177. MALAYSIA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 178. MALAYSIA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
• TABLE 179. MALAYSIA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 180. MALAYSIA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 181. MALAYSIA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 182. MALAYSIA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 183. MALAYSIA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
• TABLE 184. PHILIPPINES IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 185. PHILIPPINES IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
• TABLE 186. PHILIPPINES IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
• TABLE 187. PHILIPPINES IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 188. PHILIPPINES IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
• TABLE 189. PHILIPPINES IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 190. PHILIPPINES IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 191. PHILIPPINES IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 192. PHILIPPINES IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 193. PHILIPPINES IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
• TABLE 194. SINGAPORE IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 195. SINGAPORE IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
• TABLE 196. SINGAPORE IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
• TABLE 197. SINGAPORE IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 198. SINGAPORE IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
• TABLE 199. SINGAPORE IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 200. SINGAPORE IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 201. SINGAPORE IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 202. SINGAPORE IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 203. SINGAPORE IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
• TABLE 207. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 208. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
• TABLE 209. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 210. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 211. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 212. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 213. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
• TABLE 214. TAIWAN IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 215. TAIWAN IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
• TABLE 216. TAIWAN IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
• TABLE 217. TAIWAN IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 218. TAIWAN IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
• TABLE 219. TAIWAN IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 220. TAIWAN IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 221. TAIWAN IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 222. TAIWAN IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 223. TAIWAN IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
• TABLE 224. THAILAND IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 225. THAILAND IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
• TABLE 226. THAILAND IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
• TABLE 227. THAILAND IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 228. THAILAND IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
• TABLE 229. THAILAND IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 230. THAILAND IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 231. THAILAND IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 232. THAILAND IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 233. THAILAND IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
• TABLE 234. VIETNAM IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 235. VIETNAM IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
• TABLE 236. VIETNAM IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
• TABLE 237. VIETNAM IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 238. VIETNAM IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
• TABLE 239. VIETNAM IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 240. VIETNAM IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 241. VIETNAM IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 242. VIETNAM IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 243. VIETNAM IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
• TABLE 244. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 245. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
• TABLE 246. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
• TABLE 247. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 248. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
• TABLE 249. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 250. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 251. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 252. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 253. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
• TABLE 254. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 255. DENMARK IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 256. DENMARK IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
• TABLE 257. DENMARK IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
• TABLE 258. DENMARK IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 259. DENMARK IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
• TABLE 260. DENMARK IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 261. DENMARK IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 262. DENMARK IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 263. DENMARK IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 264. DENMARK IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
• TABLE 265. EGYPT IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 266. EGYPT IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
• TABLE 267. EGYPT IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
• TABLE 268. EGYPT IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 269. EGYPT IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
• TABLE 270. EGYPT IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 271. EGYPT IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 272. EGYPT IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 273. EGYPT IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 274. EGYPT IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
• TABLE 275. FINLAND IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 276. FINLAND IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
• TABLE 277. FINLAND IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
• TABLE 278. FINLAND IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 279. FINLAND IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
• TABLE 280. FINLAND IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 281. FINLAND IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 282. FINLAND IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 283. FINLAND IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 284. FINLAND IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
• TABLE 285. FRANCE IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 286. FRANCE IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
• TABLE 287. FRANCE IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
• TABLE 288. FRANCE IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 289. FRANCE IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
• TABLE 290. FRANCE IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 291. FRANCE IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 292. FRANCE IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 293. FRANCE IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 294. FRANCE IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
• TABLE 295. GERMANY IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 296. GERMANY IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
• TABLE 297. GERMANY IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
• TABLE 298. GERMANY IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 299. GERMANY IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
• TABLE 300. GERMANY IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 301. GERMANY IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 302. GERMANY IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 303. GERMANY IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 304. GERMANY IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
• TABLE 305. ISRAEL IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 306. ISRAEL IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
• TABLE 307. ISRAEL IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
• TABLE 308. ISRAEL IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 309. ISRAEL IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
• TABLE 310. ISRAEL IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 311. ISRAEL IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 312. ISRAEL IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 313. ISRAEL IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 314. ISRAEL IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
• TABLE 315. ITALY IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 316. ITALY IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
• TABLE 317. ITALY IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
• TABLE 318. ITALY IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 319. ITALY IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
• TABLE 320. ITALY IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 321. ITALY IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 322. ITALY IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 323. ITALY IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 324. ITALY IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
• TABLE 325. NETHERLANDS IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 326. NETHERLANDS IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
• TABLE 327. NETHERLANDS IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
• TABLE 328. NETHERLANDS IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 329. NETHERLANDS IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
• TABLE 330. NETHERLANDS IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 331. NETHERLANDS IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 332. NETHERLANDS IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 333. NETHERLANDS IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 334. NETHERLANDS IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
• TABLE 335. NIGERIA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 336. NIGERIA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
• TABLE 337. NIGERIA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
• TABLE 338. NIGERIA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 339. NIGERIA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
• TABLE 340. NIGERIA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 341. NIGERIA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 342. NIGERIA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 343. NIGERIA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 344. NIGERIA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
• TABLE 345. NORWAY IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 346. NORWAY IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
• TABLE 347. NORWAY IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
• TABLE 348. NORWAY IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 349. NORWAY IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
• TABLE 350. NORWAY IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 351. NORWAY IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 352. NORWAY IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 353. NORWAY IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 354. NORWAY IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
• TABLE 355. POLAND IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 356. POLAND IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
• TABLE 357. POLAND IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
• TABLE 358. POLAND IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 359. POLAND IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
• TABLE 360. POLAND IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 361. POLAND IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 362. POLAND IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 363. POLAND IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 364. POLAND IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
• TABLE 365. QATAR IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 366. QATAR IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
• TABLE 367. QATAR IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
• TABLE 368. QATAR IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 369. QATAR IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
• TABLE 370. QATAR IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 371. QATAR IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 372. QATAR IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
• TABLE 373. QATAR IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 374. QATAR IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
• TABLE 375. RUSSIA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 376. RUSSIA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
• TABLE 377. RUSSIA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
• TABLE 378. RUSSIA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 379. RUSSIA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)

TA

The In Vivo CRO Market was valued at USD 4.46 billion in 2023, expected to reach USD 4.87 billion in 2024, and is projected to grow at a CAGR of 9.75%, to USD 8.56 billion by 2030.

In Vivo Contract Research Organizations (CROs) specialize in providing outsourced research services that involve live animal models to pharmaceutical, biotechnology, and related industries. The necessity of in vivo CROs stems from their critical role in preclinical development, enabling clients to efficiently conduct Phase I trials by offering comprehensive services such as toxicology, pharmacology, and drug metabolism studies. The application of these services spans drug discovery, safety evaluation, and regulatory submission support, with prominent end-users including pharmaceutical companies, biotechnology firms, and research institutions. Market growth is fueled by increased R&D spending, rising demand for advanced healthcare solutions, and the ethical push for reducing animal testing through more precise data from necessary studies. Key influencing factors include technological advancements in translational research, growing biopharmaceutical pipelines, and collaborations between CROs and academia. Recent trends highlight potential opportunities in personalized medicine research, specialized disease models, and expansion into emerging markets. Recommendations for capturing these opportunities involve investing in cutting-edge technologies such as CRISPR and AI-driven data analytics, which enhance predictive accuracy and efficiency. Despite its growth potential, the in vivo CRO market faces challenges like stringent regulatory demands, ethical concerns on animal welfare, and high operational costs. To overcome these, companies should advocate for transparent ethical practices, invest in alternative methods to achieve the 3Rs (Replacement, Reduction, Refinement), and focus on automation to streamline processes. Innovation areas include developing more human-relevant models like organ-on-chips and exploring AI's role in predictive analytics to minimize resource utilization. The market exhibits a dynamic nature characterized by rapid technological changes and regulatory landscapes, necessitating stakeholders to remain adaptive and forward-thinking to sustain business growth and remain competitive.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving In Vivo CRO Market

The In Vivo CRO Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing usage of outsourcing services due to economic benefits
  • Growing investments in the pharmaceutical research by public and private sectors
  • Rising focus on the development of biosimilar medicines and drugs
• Market Restraints
  • High cost associated with the clinical trial processes
• Market Opportunities
  • Globalization of clinical trial processes
  • Competitive landscape in the pharmaceutical sector with patent applications
• Market Challenges
  • Issues related to quality control in In vivo CROs

Porter's Five Forces: A Strategic Tool for Navigating the In Vivo CRO Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the In Vivo CRO Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the In Vivo CRO Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the In Vivo CRO Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the In Vivo CRO Market

A detailed market share analysis in the In Vivo CRO Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the In Vivo CRO Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the In Vivo CRO Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the In Vivo CRO Market

A strategic analysis of the In Vivo CRO Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the In Vivo CRO Market, highlighting leading vendors and their innovative profiles. These include Charles River Laboratories, Crown Bioscience, Inc., Eurofins Scientific SE, Evotec SE, ICON Plc, Labcorp Drug Development, Medpace, Inc., MI Bioresearch, Inc., Parexel International Corporation, Pharmacology Discovery Services, PPD Inc., Syneos Health, Syngene International Limited, Taconic Biosciences, Inc., and WuXi AppTec, Inc..

Market Segmentation & Coverage

This research report categorizes the In Vivo CRO Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Non-Rodent and Rodent. The Rodent is further studied across Mice and Rats.
• Based on GLP Type, market is studied across GLP Toxicology and Non-GLP. The GLP Toxicology is further studied across In House and Outsourcing. The Non-GLP is further studied across In House and Outsourcing.
• Based on Indication, market is studied across Autoimmune/inflammation conditions, Blood Cancer, CNS conditions, Diabetes, Obesity, Oncology, Pain management, and Solid Tumor. The Autoimmune/inflammation conditions is further studied across Irritable Bowel Syndrome, Multiple Sclerosis, Osteoarthritis, and Rheumatoid Arthritis. The CNS conditions is further studied across ALS, Epilepsy, Huntington's Disease, Muscle Regeneration, Parkinson's Disease, Stroke, and Traumatic Brain Injury. The Pain management is further studied across Acute Pain and Chronic Pain. The Solid Tumor is further studied across Patient-derived Xenograft, Syngeneic Model, and Xenograft.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing usage of outsourcing services due to economic benefits
    • 5.1.1.2. Growing investments in the pharmaceutical research by public and private sectors
    • 5.1.1.3. Rising focus on the development of biosimilar medicines and drugs
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with the clinical trial processes
  • 5.1.3. Opportunities
    • 5.1.3.1. Globalization of clinical trial processes
    • 5.1.3.2. Competitive landscape in the pharmaceutical sector with patent applications
  • 5.1.4. Challenges
    • 5.1.4.1. Issues related to quality control in In vivo CROs
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. In Vivo CRO Market, by Type

• 6.1. Introduction
• 6.2. Non-Rodent
• 6.3. Rodent
  • 6.3.1. Mice
  • 6.3.2. Rats

7. In Vivo CRO Market, by GLP Type

• 7.1. Introduction
• 7.2. GLP Toxicology
  • 7.2.1. In House
  • 7.2.2. Outsourcing
• 7.3. Non-GLP
  • 7.3.1. In House
  • 7.3.2. Outsourcing

8. In Vivo CRO Market, by Indication

• 8.1. Introduction
• 8.2. Autoimmune/inflammation conditions
  • 8.2.1. Irritable Bowel Syndrome
  • 8.2.2. Multiple Sclerosis
  • 8.2.3. Osteoarthritis
  • 8.2.4. Rheumatoid Arthritis
• 8.3. Blood Cancer
• 8.4. CNS conditions
  • 8.4.1. ALS
  • 8.4.2. Epilepsy
  • 8.4.3. Huntington's Disease
  • 8.4.4. Muscle Regeneration
  • 8.4.5. Parkinson's Disease
  • 8.4.6. Stroke
  • 8.4.7. Traumatic Brain Injury
• 8.5. Diabetes
• 8.6. Obesity
• 8.7. Oncology
• 8.8. Pain management
  • 8.8.1. Acute Pain
  • 8.8.2. Chronic Pain
• 8.9. Solid Tumor
  • 8.9.1. Patient-derived Xenograft
  • 8.9.2. Syngeneic Model
  • 8.9.3. Xenograft

9. Americas In Vivo CRO Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific In Vivo CRO Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa In Vivo CRO Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Charles River Laboratories
• 2. Crown Bioscience, Inc.
• 3. Eurofins Scientific SE
• 4. Evotec SE
• 5. ICON Plc
• 6. Labcorp Drug Development
• 7. Medpace, Inc.
• 8. MI Bioresearch, Inc.
• 9. Parexel International Corporation
• 10. Pharmacology Discovery Services
• 11. PPD Inc.
• 12. Syneos Health
• 13. Syngene International Limited
• 14. Taconic Biosciences, Inc.
• 15. WuXi AppTec, Inc.